Details for Patent: 6,004,972
✉ Email this page to a colleague
| Title: | Therapeutic process for the treatment of the pathologies of type II diabetes |
| Abstract: | A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects. |
| Inventor(s): | Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA) |
| Assignee: | The Board of Supervisiors of Louisiana State University and Agricultural (Baton Rouge, LA) |
| Filing Date: | Jun 23, 1998 |
| Application Number: | 09/103,105 |
| Claims: | 1. A process for the therapeutic modification and regulation of glucose metabolism in an animal or human subject, which comprises administering to a subject in need of treatment, on a timed daily basis a dopamine agonist in dosage amount and for a period sufficient to reduce plasma glucose levels in said animal or human subject. 2. The process of claim 1 wherein the administration of said dopamine agonist is confined to the period during the day proximate to the time of day at which the serum prolactin concentration of young, lean, insulin-sensitive animal of the same sex and species is low. 3. The process of claim 1 wherein said subject is a human and the dopamine agonist is given daily confined to a time or times ranging from about 4 hours to about 8 hours after the time corresponding to that in which the prolactin concentration peaks in a lean insulin sensitive person. 4. The process of claim 1 wherein said subject is a human and the dopamine agonist is given daily confined to a time or times ranging from about 0 hours to about 5 hours after awakening. 5. The process of claim 1 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 6. The process of claim 2 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 7. The process of claim 3 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 8. The process of claim 4 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 9. In a method for treating an animal or human subject exhibiting one or more of obesity, type-II diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, or hyperglycemia by delivery to said subject of a dopamine agonist, the improvement which comprises: administering to said subject in need of such treatment, on a timed daily basis, a dopamine agonist in dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 10. The process of claim 9 wherein the administration of said dopamine agonist is confined to the period during the day proximate to the time of day at which the serum prolactin concentration of a young, lean, insulin-sensitive subject of the same sex and species is low. 11. A method for treating an animal or human subject exhibiting one or more of obesity, type-II diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, or hyperglycemia, comprising: administering to said subject in need of such treatment, on a timed daily basis, a dopamine agonist in dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 12. The process of claim 11 wherein the administration of said dopamine agonist is confined to the period during the day proximate to the time of day at which the serum prolactin concentration of a young, lean, insulin-sensitive subject of the same sex and species is low. 13. The process of claim 11 herein said subject is a human and the dopamine agonist is given daily confined to a time or times ranging from about 4 hours to about 8 hours after the time corresponding to that in which the prolactin concentration peaks in a lean insulin sensitive person. 14. The process of claim 11 wherein said subject is a human and the dopamine agonist is given daily confined to a time or times ranging from about 0 hours to about 5 hours after awakening. 15. The process of claim 11 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 16. The process of claim 12 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 17. The process of claim 13 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 18. The process of claim 14 wherein said subject is human, said dopamine agonist is bromocriptine, and the timed daily dosages of bromocriptine are given daily, once a day at levels ranging from about 3 micrograms to about 100 micrograms, per pound of body weight. 19. The process of claim 11 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 20. The process of claim 12 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 21. The process of claim 13 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 22. The process of claim 14 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 23. The process of claim 15 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 24. The process of claim 16 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 25. The process of claim 17 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 26. The process of claim 18 wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia. 27. The process of claim 11 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 28. The process of claim 12 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 29. The process of claim 13 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 30. The process of claim 14 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 31. The process of claim 15 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 32. The process of claim 16 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 33. The process of claim 17 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 34. The process of claim 18 wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia. 35. The process of claim 8 wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening. 36. The process of claim 18 wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening. 37. The process of claim 26 wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening. 38. The process of claim 34 wherein said bromocriptine is given daily confined to a time or time ranging from about 0 hours to about 3 hours after awakening. |
